WuXi Apptec Resumes Operations at Wuhan Site

Article

The facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.

WuXi AppTec announced on March 10, 2020 that it has resumed operations at its Wuhan, China, site in agreement with local regulations and global novel coronavirus (COVID-19) health and safety guidelines.

According to a company press release, the facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.

“We are working with our employees and suppliers to reach steady state operations at our Wuhan site as soon as possible,” said Steve Yang, executive vice-president and chief business officer of WuXi AppTec, in a company press release. “We value our customers’ contributions to the healthcare field and put them first by providing timely and world-class quality service and continue to do the right thing for patients-a goal that WuXi AppTec has pursued since its founding.”

Source: WuXi AppTec

 

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.